Stockholm, Sweden

Rohit Batta

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Rohit Batta: Innovator in Pulmonary Fibrosis Treatment

Introduction

Rohit Batta is a prominent inventor based in Stockholm, Sweden. He has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis. With a total of 4 patents to his name, Batta is recognized for his innovative approaches to healthcare.

Latest Patents

One of Rohit Batta's latest patents focuses on the treatment of idiopathic pulmonary fibrosis. The invention provides a method for improving or restoring function in patients suffering from this condition. This method involves the peroral administration of a therapeutically effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof. The treatment is capable of addressing idiopathic pulmonary fibrosis in a therapeutic and potentially curative manner.

Career Highlights

Rohit Batta is currently associated with Vicore Pharma AB, where he continues to develop innovative solutions for pulmonary diseases. His work has garnered attention in the medical community, and he is recognized for his dedication to improving patient outcomes.

Collaborations

Rohit collaborates with notable colleagues, including Carl-Johan Dalsgaard and Johan Raud. These partnerships enhance the research and development efforts at Vicore Pharma AB, contributing to advancements in medical treatments.

Conclusion

Rohit Batta's contributions to the treatment of idiopathic pulmonary fibrosis highlight his role as an innovator in the medical field. His patents and ongoing work at Vicore Pharma AB demonstrate his commitment to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…